First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: A meta-analysis of observational studies

Stephanie Dellicour, Esperança Sevene, Rose McGready, Halidou Tinto, Dominic Mosha, Christine Manyando, Stephen Rulisa, Meghna Desai, Peter Ouma, Martina Oneko, Anifa Vala, Maria Rupérez, Eusébio Macete, Clara Menéndez, Seydou Nakanabo-Diallo, Adama Kazienga, Innocent Valéa, Gregory Calip, Orvalho Augusto, Blaise Genton, Eric M Njunju, Kerryn A Moore, Umberto d’Alessandro, Francois Nosten, Feiko ter Kuile and Andy Stergachis

PLOS Medicine, 2017, vol. 14, issue 5, 1-20

Abstract: Background: Animal embryotoxicity data, and the scarcity of safety data in human pregnancies, have prevented artemisinin derivatives from being recommended for malaria treatment in the first trimester except in lifesaving circumstances. We conducted a meta-analysis of prospective observational studies comparing the risk of miscarriage, stillbirth, and major congenital anomaly (primary outcomes) among first-trimester pregnancies treated with artemisinin derivatives versus quinine or no antimalarial treatment. Methods and findings: Electronic databases including Medline, Embase, and Malaria in Pregnancy Library were searched, and investigators contacted. Five studies involving 30,618 pregnancies were included; four from sub-Saharan Africa (n = 6,666 pregnancies, six sites) and one from Thailand (n = 23,952). Antimalarial exposures were ascertained by self-report or active detection and confirmed by prescriptions, clinic cards, and outpatient registers. Cox proportional hazards models, accounting for time under observation and gestational age at enrollment, were used to calculate hazard ratios. Individual participant data (IPD) meta-analysis was used to combine the African studies, and the results were then combined with those from Thailand using aggregated data meta-analysis with a random effects model. Conclusions: Compared to quinine, artemisinin treatment in the first trimester was not associated with an increased risk of miscarriage or stillbirth. While the data are limited, they indicate no difference in the prevalence of major congenital anomalies between treatment groups. The benefits of 3-d artemisinin combination therapy regimens to treat malaria in early pregnancy are likely to outweigh the adverse outcomes of partially treated malaria, which can occur with oral quinine because of the known poor adherence to 7-d regimens. Review registration: PROSPERO CRD42015032371 In a meta-analysis using individual patient data from prospective observational studies, Andy Stergachis and colleagues investigate the risk of of miscarriage, stillbirth, and major congenital anomaly among pregnancies that were treated during the first trimester with artemisinin derivatives versus quinine or no antimalarial treatment.Why was this study done?: What did the researchers do and find?: What do these findings mean?:

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002290 (text/html)
https://journals.plos.org/plosmedicine/article/fil ... 02290&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pmed00:1002290

DOI: 10.1371/journal.pmed.1002290

Access Statistics for this article

More articles in PLOS Medicine from Public Library of Science
Bibliographic data for series maintained by plosmedicine ().